Therefore, novel therapeutic strategies to eliminate the c-FLIP-mediated chemoresistance of HCC cells are required, and the identification of novel therapeutic compounds with anti-HCC activity, particularly those derived from naturally occurring materials, is necessary. This evidence concerns the gene CFLAR and hepatocellular carcinoma.